202 related articles for article (PubMed ID: 29777564)
1. Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer.
Ali A; Hoyle A; Mistry H; Clarke NW
BJU Int; 2019 Jan; 123(1):65-73. PubMed ID: 29777564
[TBL] [Abstract][Full Text] [Related]
2. Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
Heesterman BL; van der Poel HG; Schoots IG; Mehra N; Aben KKH
BJU Int; 2022 Aug; 130(2):217-225. PubMed ID: 34741789
[TBL] [Abstract][Full Text] [Related]
3. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer.
Gandaglia G; Karakiewicz PI; Briganti A; Passoni NM; Schiffmann J; Trudeau V; Graefen M; Montorsi F; Sun M
Eur Urol; 2015 Aug; 68(2):325-34. PubMed ID: 25108577
[TBL] [Abstract][Full Text] [Related]
4. Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality.
Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Soulières D; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2018 Oct; 16(5):376-384.e1. PubMed ID: 29954690
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Young Age and Non-Bone Metastasis at Diagnosis in Patients with Metastatic Prostate Cancer: a SEER Population-Based Data Analysis.
Guo Y; Mao S; Zhang A; Wang R; Zhang Z; Zhang J; Wang L; Zhang W; Wu Y; Ye L; Yang B; Yao X
J Cancer; 2019; 10(3):556-567. PubMed ID: 30719152
[No Abstract] [Full Text] [Related]
6. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
7. Surgery on Metastatic Foci is a Better Strategy for Stage IV Breast Cancer Patients with only Nonregional Lymph Node Metastasis.
Jiao Y; Guo X; Wu H; Lv Q
Adv Ther; 2023 Jul; 40(7):3247-3262. PubMed ID: 37270436
[TBL] [Abstract][Full Text] [Related]
8. Influence of nonregional lymph node metastasis as a prognostic factor in metastatic prostate cancer patients.
Cho S; Kang SG; Tae BS; Cheon J
Korean J Urol; 2012 Oct; 53(10):673-9. PubMed ID: 23136626
[TBL] [Abstract][Full Text] [Related]
9. Regional Lymph Node Involvement Is Associated With Poorer Survivorship in Patients With Chondrosarcoma: A SEER Analysis.
Wan L; Tu C; Li S; Li Z
Clin Orthop Relat Res; 2019 Nov; 477(11):2508-2518. PubMed ID: 31283732
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients.
Budnik J; Suri J; Bates JE; Bylund KC; Milano MT
Clin Genitourin Cancer; 2019 Aug; 17(4):260-267. PubMed ID: 31101579
[TBL] [Abstract][Full Text] [Related]
11. Impact of non-regional lymph node metastases accurately revealed on
Jiang Z; Fan J; Gan C; Dong X; Gao G; Wang Z; He D; Li L; Duan X; Wu K
EJNMMI Res; 2023 Jul; 13(1):64. PubMed ID: 37410264
[TBL] [Abstract][Full Text] [Related]
12. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.
Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
JAMA Oncol; 2015 Jun; 1(3):334-40. PubMed ID: 26181182
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
Rii J; Sakamoto S; Yamada Y; Takeshita N; Yamamoto S; Sazuka T; Imamura Y; Nakamura K; Komiya A; Komaru A; Fukasawa S; Nakatsu H; Akakura K; Ichikawa T
Prostate; 2020 Aug; 80(11):850-858. PubMed ID: 32501559
[TBL] [Abstract][Full Text] [Related]
14. Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer.
Xiang M; Nguyen PL
Brachytherapy; 2015; 14(6):773-80. PubMed ID: 26489921
[TBL] [Abstract][Full Text] [Related]
15. Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases.
Bernstein AN; Shoag JE; Golan R; Halpern JA; Schaeffer EM; Hsu WC; Nguyen PL; Sedrakyan A; Chen RC; Eggener SE; Hu JC
J Urol; 2018 Jun; 199(6):1510-1517. PubMed ID: 29288121
[TBL] [Abstract][Full Text] [Related]
16. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.
Bryant AK; Kader AK; McKay RR; Einck JP; Mell LK; Mundt AJ; Kane CJ; Efstathiou JA; Murphy JD; Rose BS
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1188-1193. PubMed ID: 29891203
[TBL] [Abstract][Full Text] [Related]
17. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
18. Risk Evaluation of Bone Metastases and a Simple Tool for Detecting Bone Metastases in Prostate Cancer: A Population-Based Study.
Li S; Chen C; Zhu H; Lin Q; Yu Z
Comput Math Methods Med; 2023; 2023():9161763. PubMed ID: 36824150
[TBL] [Abstract][Full Text] [Related]
19. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study.
Bandini M; Pompe RS; Marchioni M; Zaffuto E; Gandaglia G; Fossati N; Cindolo L; Montorsi F; Briganti A; Saad F; Karakiewicz PI
Int Urol Nephrol; 2018 Jan; 50(1):71-78. PubMed ID: 29129028
[TBL] [Abstract][Full Text] [Related]
20. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
